Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Our latest clients all have the potential to grow significantly in the near and long-term future

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jan 09, 2018 5:31 pm

Intriguing Research into Pathways to Limit Nicotine, Quit Cigarette Use

NetworkNewsWire Editorial Coverage: It’s no secret that cigarettes, a product whose toxins and carcinogens have shown time and again to cause illness and a long list of cancers, are addictive. Finding a way to stop smoking is an individual battle, although there is hope that new products are on the horizon that may help millions of people win the fight. Several significant research and development projects being undertaken by such innovators such as Lexaria Bioscience Corp. (CSE:LXX) (OTCQX: LXRP) (LXRP Profile) a company with proprietary technology capable of changing the way active pharmaceutical ingredients (“APIs”) such as nicotine enter the body. Even leading tobacco brands like British American Tobacco p.l.c. (NYSE: BTI), Philip Morris International (NYSE: PM), Altria Group Inc. (NYSE: MO) and Universal Corporation (NYSE: UVV) are showing interest in contributing to the shift toward nicotine-infused products and away from combustible cigarettes.

What, No Smoke?

That’s the goal, isn’t it? Products on the market today meant to help smokers “kick the habit” are behind the counter of nearly every store that carries dozens of cigarette brands. The U.S. Food and Drug Administration has approved several forms of nicotine replacement therapy such as gum, transdermal patches, sprays, inhalers or lozenges, and all are meant to help relieve some of the physical withdrawal symptoms when a person tries to quit smoking (http://nnw.fm/2Nd9L). Interestingly, the legal age for tobacco products and inhalant delivery system such as e-cigarettes in Oregon was just raised from 18 to 21, effective January 1, 2018. That legislation puts Oregon in company with California, Hawaii, Maine and New Jersey as the only states with such a legal limit (http://nnw.fm/d12X2). The goal, according to state officials, is to stop young people from first picking up a cigarette and avoid joining the millions of people who die each year because of tobacco use.

Promising Research

Research teams at Lexaria Bioscience Corp. (CSE:LXX) (OTCQB: LXRP), based in Kelowna, British Columbia, Canada, have developed a new, disruptive drug delivery platform called “DehydraTECH™ that changes the way APIs enter the body via oral consumption. Lexaria’s patented delivery method could give the estimated 69 percent of U.S. adult smokers who say they want to quit a new way to do just that. Utilizing Lexaria’s DehydraTECH™ technology to formulate edible products containing nicotine and/or its analogues for this purpose offers unique advantages to the consumer. The company’s newly issued U.S. patent award covers the use of DehydraTECH™ technology as a broad delivery platform for a broad range of APIs, including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications (“NSAIDs”), and nicotine (http://nnw.fm/Do3iO).

“This wide-ranging patent allowance from the U.S. Patent and Trademark Office exceeds our expectations” Lexaria Bioscience Chief Executive Officer Chris Bunka stated in a press release (http://nnw.fm/4NAWd). “This vastly expanded intellectual property protection will enable us to aggressively pursue new business opportunities in 2018 such as what could be the world’s first nicotine edibles for the smokeless tobacco industry, or enhanced products for NSAID-derived pain management, as well as in the rapidly growing cannabis market.”

Advanced Delivery Method

Lexaria is accelerating its research focus on nicotine following its patent grant and is preparing formulations of edible forms of nicotine using the DehydraTECH™ technology. These formulations are currently completing quality control testing prior to in vivo absorption and tolerability testing. A third-party laboratory is expected to perform the first nicotine edible tests in February 2018. Imagine an edible nicotine-infused product that: masks unwanted tastes, eliminating the need for sugar-filled edibles; reduces the time of onset with effects felt within 15-20 minutes instead of up to an hour or more; avoids first-pass liver metabolism, which means fewer side effects; and increases bio-absorption by five to 10 times which equates to an inhaled delivery method – all while helping you quit smoking cigarettes.

Spotlight on Innovation

The FDA’s recent proposal to reduce nicotine levels in cigarettes to non-addictive levels bodes well for companies like Lexaria whose patented technology clearly supports the effort. Almost 90 percent of adult smokers started smoking before the age of 18 and nearly 2,500 youth smoke their first cigarette every day in the U.S., and the FDA’s comprehensive plan for tobacco and nicotine regulation will serve as a multiyear roadmap to better protect children and significantly reduce tobacco-related disease and death (http://nnw.fm/2SUkk). Lowering nicotine levels could decrease the likelihood that future generations become addicted to cigarettes and allow more currently addicted smokers to quit.

Market Implications

The company’s proprietary platform allows for the infusion of nicotine molecules within a wide range of edible food ingredients or typical capsule formats, effectively opening the door for the creation of a new product category targeting the high-demand smoking cessation market (http://nnw.fm/vmNg7). While this research is in its early stages, the market implications of maximizing Lexaria’s patented molecular delivery method in such areas as nicotine delivery, non-steroidal anti-inflammatories (NSAIDs) and vitamins – all multibillion dollar industries – is significant. According to a 2016 report by Grand View Research, Inc., the global smoking cessation and nicotine de-addiction market is expected to reach over $21.8 billion by 2024. As Grand View reports, “The launch of… improved and innovative nicotine replacement therapy products is to serve as a high impact rendering driver for the growth of the smoking cessation and nicotine de-addiction market (http://nnw.fm/Ytnr1)”

Big Tobacco’s Take

The FDA’s mandate is even being touted by big tobacco companies whose fortunes once solely rested on its combustible offerings. Smoke-free options are rapidly becoming popular as the National Institute on Drug Abuse reports they often are chosen by those wishing to lower nicotine cravings in their quest to stop smoking cigarettes (http://nnw.fm/bM5vN). The FDA’s directive to lower nicotine in cigarettes to non-addictive or less addictive levels is driving much of the industry’s research and development drive. With more tobacco companies acknowledging the hazards of smoking and changing their approach to nicotine consumption, Lexaria could have incredible potential as a solution provider with its advanced delivery system.

British American Tobacco p.l.c. (NYSE: BTI), a global tobacco and nicotine products company, sells its products in more than 200 markets worldwide. The company’s push to develop “Next Generation Products,” such as e-cigarettes and tobacco-heating products comes with a reminder that although these products are not entirely without risk, they are considered to be significantly less than smoking combustible cigarettes (http://nnw.fm/ss8Nv).

Philip Morris International (NYSE: PM), one of the three largest tobacco companies in the world, trumpets its intention to design a “smoke-free future” right on the front page of the company website, asking readers “How long will PMI be in the cigarette business?” (http://nnw.fm/7Mih6). The company states it is developing and testing products that deliver nicotine without the harmful smoke of cigarettes. In fact, Phillip Morris said its New Year’s resolution is to give up cigarettes (http://nnw.fm/Q2Dc1) and took out full-page ads in several newspapers in the United Kingdom that reiterated its ambition.

Altria Group Inc. (NYSE: MO) is another global tobacco company based in the United States focused on addressing these same issues of reducing the health effects of tobacco use. “Reduced risk” tobacco products are reportedly part of Altria’s future, with many industry analysts expecting this category to be a major growth driver in 2018 (http://nnw.fm/vr3Ys). Regulatory hurdles along with limitations on marketing campaigns, a growing anti-smoking push and higher excise taxes are all dragging tobacco companies down.

Leading tobacco leaf supply company Universal Corporation (NYSE: UVV) doesn’t make cigarettes or tobacco products, but the Virginia-based company is still affected by the public’s growing aversion to combustible cigarettes. Universal states on its website that the company believes growth in world consumption of cigarettes peaked several years ago and is declining. While its clients remain the six largest tobacco companies in the world, Universal is also investing in alternative forms of revenue (http://nnw.fm/0VKe0). The company’s AmeriNic joint venture seeks to produce liquid nicotine for the vapor products industry, which may prove to be a lucrative change from the conventional tobacco end market.

A Bright Future

Lexaria, which upgraded to the OTCQB Venture Market on January 4, 2018, expects this to provide an unqualified positive opportunity for investors as the company continues to build its disruptive technology and create innovative products for the cannabis industry and nicotine-suppression markets.

“Lexaria has made notable progress over the past twelve months in all aspects of its business, and will receive even more recognition by upgrading to OTCQX,” CEO Bunka stated in the press release announcing the uplisting. “Lexaria expects to provide greater visibility and liquidity for our investors on OTCQX as we build our disruptive technology innovations through 2018 and beyond.”

For more information on Lexaria Bioscience, visit: Lexaria Bioscience Corp. (CSE:LXX) (OTCQB: LXRP)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Jan 11, 2018 6:36 pm

2017 was a Transformative Year for Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

- Lexaria’s CEO posts end of 2017 summary
- Multiple transformative developments – IP strengthened, broad patents awarded, finances secured
- Foundation for the future established – multiple opportunities on horizon

If the past is any prologue, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) should have a break out year in 2018. Lexaria’s CEO, Chris Bunka, recently posted ‘LXRP CEO’s End of 2017 Summary’. It was a transformative year with multiple accomplishments that should establish a strong foundation for the future.

Lexaria Bioscience has developed, patented and commercialized a cost-effective lipophilic delivery technology, DehydraTECH™, to enhance the performance of beneficial compounds in ingestible products. Already scientifically proven to enhance absorption of orally ingested cannabinoids, Lexaria’s novel drug delivery platform is believed to be applicable across a wide range of different vitamins, drug types and cannabinoids, dramatically impacting bio-absorption and bioavailability, as well as taste, smell and speed of action.

Lexaria’s DehydraTECH™ technology is a potential game changer for the delivery methodologies of many commonly used active pharmaceutical substances. The technology provides an additional layer of effectiveness designed to harmonize with the intellectual properties of manufacturers, and it can be used with both patented and generic pharmaceutical substances. This breakthrough plays into Lexaria’s long term strategy to partner with leading pharmaceutical, biopharma, nutraceutical, vitamin and food companies to make payload delivery more predictable, safer and more effective.

The first item addressed in the CEO summary was company finances. With a commitment to enhancing shareholder value, Lexaria cleaned up its balance sheet, raised well over $4 million and paid off all its debt. With cash in the bank, the company announced a $1 million budget for R&D using its patented DehydraTECH™ absorption and palatability-enhancing technology to create even more long term value. The company continued multiple absorption tests and formulation experiments, and it continues to pursue a number of intellectual property (IP) enhancement procedures to expand its IP portfolio.

The most significant and transformational developments of 2017 centered on the incredible value created with Lexaria’s intellectual properties. Late in 2016, Lexaria received its first U.S. patent award. Then, in the first half of 2017, the company received its first patent award in Australia. Lexaria announced in November that it had received a broad ranging U.S. patent award for its DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients. The U.S. patent includes all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine. Lexaria is continuing to advance all of its 33 other patent applications pending around the world. The impact of these patents not only creates value and validates Lexaria’s technology; it also opens untold avenues of business opportunity, some of which may be realized over the course of the coming year.

Lexaria has also taken large positions in subsidiary companies that could benefit from the global liberalization of cannabis. Lexaria owns 50 percent of Ambarii Trade Corp., which may offer international opportunities for a class of mouth-melt consumer products delivered with Lexaria’s technology. Lexaria consolidated ownership of PoViva Tea LLC and now own 100 percent. The company also successfully introduced TurboCBD™, a 100 percent-owned brand of hemp oil empowered with DehydraTECH™.

The company’s stock has performed well over the last year and, given all the progress, may outperform in 2018. Lexaria up-listed to the larger, more recognized OTCQX market, and the company filed an S4 prospectus to re-domicile the company from the U.S. to Canada in an effort to exploit opportunities in the Canadian cannabinoid products sector.

As the abundance of good news from last year begins to sink in, it certainly appears that Lexaria is making all the right moves to make 2018 even better.

For more information, visit the company’s website at www.LexariaBioscience.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Jan 19, 2018 7:07 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) demonstrated several transformative developments in 2017. The company’s Intellectual Property (“IP”) was strengthened, it was awarded broad patents, and it secured finances during the year. Now, Lexaria is concentrating on making 2018 an even more fruitful year. An article discussing the company’s recent progress reads: “The company’s stock has performed well over the last year and, given all the progress, may outperform in 2018. Lexaria up-listed to the larger, more recognized OTCQX market, and the company filed an S4 prospectus to re-domicile the company from the U.S. to Canada in an effort to exploit opportunities in the Canadian cannabinoid products sector.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Jan 23, 2018 4:55 pm

Disrupting Drug Delivery Platform Keeps Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Portfolio Growing

- Patented technology promotes healthier administration of active pharmaceutical ingredients, including cannabidiol (CBD), psychoactive cannabinoids (THC), nicotine, fat soluble vitamins and nonsteroidal anti-inflammatory drugs
- Active pharmaceutical ingredient market expected to exceed $239 billion by 2025
- 19 patent applications filed in U.S. and internationally encompassing 44 countries
- Lab tests in 2018 include topical CBD skin cream, nicotine in edible formats

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://nnw.fm/1gI1m), the global API market is anticipated to reach $239.8 billion by 2025, with a CAGR of six percent. The rising prevalence of chronic health issues such as neurological and cardiovascular diseases are identified as growth factors.

Lexaria recently received a broad-ranging U.S. patent award for DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients. The U.S. patent covers all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine (http://nnw.fm/0Ciiq). LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in the U.S. (and internationally using the Patent Cooperation Treaty) and national filings in 44 countries.

“Lexaria has now locked-up the IP for its next-generation drug delivery system,” Chief Executive Officer Chris Bunka said in a news release announcing the U.S. patent award (http://nnw.fm/9CxwV). “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world’s first nicotine edibles for the smokeless tobacco industry, or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market.”

Through the application of Lexaria’s revolutionary DehydraTECH™ platform to specific compounds in the cannabis plant, for instance, issues such as bad taste, delay of onset, unwanted side effects and poor absorption are eliminated. Lexaria’s technology transforms the way cannabinoids enter the bloodstream through the gastrointestinal tract, providing a fast-acting, tasteless product with increased bioavailability. The company’s innovative technology solves multiple problems and offers third-party partners and distributors the ability to focus on creating safe, standardized products with mass appeal (http://nnw.fm/EU3oN).

Regulations affecting the legal cannabis industry in the U.S. and Canada underscore the need for DehydraTECH™ and its commercial application potential for edible cannabinoid products. Smoking cannabis is prohibited or limited to specific locations, and there are regulations governing the appearance and amount of psychoactive compounds allowed in edible cannabis products (http://nnw.fm/CfVK1). Regulations governing the rapidly changing cannabis industry, along with market trends, increase the need for fast-acting, high-absorption, alternative delivery methods – which is Lexaria’s specific focus.

While 2017 was a transformative year for Lexaria, the company expects 2018 to be even more significant for its shareholders as testing commences with DehydraTech™ in nicotine edibles and a topical skin cream infused with cannabinoids. The company’s strategic focus is on out-licensing DehydraTECH™ to third-party partners using a high margin royalty model. Lexaria’s first licensee in the edible cannabis space is a chocolate/cannabis company located in Colorado. Advanced discussions are also underway with additional U.S. edibles manufacturers that range from $5 million to $50 million in annual sales.

President John Docherty is slated to discuss the company’s strategic partnerships and the necessity of focused business models such as the ones guiding Lexaria during the International Cannabis Business Conference scheduled February 1-2 in San Francisco.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Jan 25, 2018 8:16 pm

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Expands Portfolio

Food bioscience company Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) strategic focus for 2018 is on out-licensing its proprietary technology, DehydraTECH™. The company intends to out-license to third-party partners using a high margin royalty model. An article discussing the company’s drug delivery platform reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://nnw.fm/1gI1m), the global API market is anticipated to reach $239.8 billion by 2025, with a CAGR of six percent. The rising prevalence of chronic health issues such as neurological and cardiovascular diseases are identified as growth factors.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Jan 26, 2018 8:09 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Offers Potentially Safer Method of Delivering Drug Therapies

- Only company in the world with patent for the oral or ingestible delivery of all non-psychoactive cannabinoids
- Uplisted to OTCQX® Best Market
- Licensing model generates profit margins in excess of 90 percent

A new report by the National Academies of Sciences, Engineering and Medicine is the most comprehensive analysis of existing research on e-cigarettes, according to the New York Times (http://nnw.fm/Ga5hZ). While warning against the risk of nicotine addiction posed by vaping, the report claimed “that the devices are safer than traditional smoking products and may help smokers quit, citing conclusive proof that switching can reduce smokers’ exposure to deadly tar, dangerous chemicals and other carcinogens.” Although nicotine is most often cited in indictments against smoking, it is not a carcinogen and appears to have little effect on cardiovascular health. Indeed, its use has been credited with health benefits (http://nnw.fm/88eiG), with its bad rap being attributed to its method of delivery, such as inhaling tobacco smoke. This report highlights the importance of drug delivery methodologies like those developed by Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP). The company, recently uplisted to the OTCQX® Best Market, has developed technology that allows nicotine to be absorbed without smoking.

Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to the 60-90 minutes required for current methods, and is already in use in a number of consumer products. The technology is already attracting the attention of Big Pharma, and Lexaria is in negotiations with major pharmaceutical companies to license its technology. The smallest deal with any one of these could increase revenues by over $1 million, and the largest could increase revenues by much, much more, as noted by CEO Chris Bunka in a recent interview (http://nnw.fm/wF0yW). Lexaria’s licensing model will generate revenues at very little cost, leaving upward of 90 percent of revenues as profit.

Presently, Lexaria is the only company in the world that has been awarded a patent for the improved (oral or ingestible, including pills) delivery of all non-psychoactive cannabinoids. Patents have been awarded in the U.S. and Australia and are pending in 40 more countries. This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs. Rather than being a competitor to clinical stage biotech companies, Lexaria plans to be an enabler.

Earlier this month, OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, announced that Lexaria Bioscience Corp. had qualified to trade on the OTCQX® Best Market (http://nnw.fm/A0KSo). Lexaria upgraded to OTCQX from the OTCQB® Venture Market. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws and have a professional third-party sponsor introduction. Penny stocks, shells and companies in bankruptcy cannot qualify for OTCQX. Per the OTC Markets website, the companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Jan 29, 2018 5:26 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has developed DehydraTECH™, a drug delivery platform that can be applied to various ingestible products such as foods, beverages, oral suspensions, tablets, capsules and more. An article discussing the company’s innovative drug delivery technology reads: “Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system offers the promise of potentially reducing required doses of these substances, since less of them goes to waste. The technology also speeds up delivery. It can deliver payload molecules to the bloodstream in 15-25 minutes, as opposed to the 60-90 minutes required for current methods, and is already in use in a number of consumer products. The technology is already attracting the attention of Big Pharma, and Lexaria is in negotiations with major pharmaceutical companies to license its technology.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Fri Feb 02, 2018 6:37 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement with Cannabis-Infused Edibles Manufacturer

- Lexaria enters agreement with Cannfections to develop an innovative range of cannabis-infused chocolates and gummies incorporating its proprietary technology, DehydraTECH™
- Cannfection’s formulation and manufacturing expertise can be offered to other Lexaria licensee partners
- The agreement is expected to generate new cannabis-based edible products for domestic and international markets

On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://nnw.fm/9DgLc). Cannfections is a new company, established by one of Canada’s leading chocolate manufacturers with over 85 years of experience in the production of high-quality chocolate and confectionery products for several prominent domestic and international chocolate brands. Cannfections is a pending entrant to the Licensed Producer program for cannabis-infused products.

Under this agreement, Lexaria is able to offer other licensee partners the use of Cannfections’ formulation and manufacturing expertise for the production of cannabis-infused chocolates and gummies, powered by Lexaria’s patented DehydraTECH™ delivery technology. This is expected to generate new product entries for Canadian cannabis edibles for the domestic market, as well as the growing number of international markets.

DehydraTECH™ is a patented, cost-effective and proven delivery technology that enhances the taste, smell, speed of action, bioabsorption and bioavailability of beneficial compounds in ingestible products. This technology has been awarded patents in the United States and Australia, and it has patents pending in 44 other countries. Lexaria is the only company in the world with a patent for the oral delivery of all non-psychoactive cannabinoids, such as cannabidiol (CBD). Lexaria’s patents involve the use of its proprietary technology for oral delivery of an extensive range of lipophilic active compounds, including cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), vitamins and nicotine.

Lexaria’s proprietary DehydraTECH™ technology masks recognition of the flavor and odor of compounds by oral and olfactory receptors. It enables manufacturers to create healthier, low-sugar products by eliminating the sugars and sweeteners traditionally used in product formulations to mask bitter tastes and unpleasant smells. This technology also increases the bioabsorption of cannabinoids and other active ingredients by up to 10 times. While other delivery technologies typically take between 60 and 120 minutes to take effect, DeydraTECH™ has been proven to register the onset of effects within 15 to 20 minutes.

Consumers benefit significantly from the enhanced taste of edibles and the reduced time to effect. As a disruptor in the growing cannabis market, Lexaria’s technology can either reduce the cannabinoid per serving unit cost, or deliver stronger effects where serving levels are regulated. The company’s technology can be applied to the manufacture of diverse product dosage forms, including foods, emulsions, liquids, tablets and capsules. Lexaria has produced a range of products for testing, demonstration and sales. These include CBD tablets, protein energy bars, exotic teas and TurboCBD, a high-absorption hemp oil capsule containing ginseng and ginkgo.

Lexaria has signed several royalty agreements for the use of its proprietary delivery technology with companies in Canada and the United States. Its latest venture with Cannfections is another step in the company’s ongoing pursuit of strategic partnerships with leading global companies to expand adoption of its innovative technology and deliver increased value for shareholders.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Feb 06, 2018 5:12 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement to Create Cannabis-infused Edibles Utilizing DehydraTECH™ Delivery Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently entered an agreement with a cannabis-infused edibles manufacturer, Cannfections Group Inc. The agreement is expected to generate new cannabis-based edible products using Lexaria’s patented DehydraTECH™ delivery technology. An article discussing the agreement reads: “On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://nnw.fm/9DgLc). Cannfections is a new company, established by one of Canada’s leading chocolate manufacturers with over 85 years of experience in the production of high-quality chocolate and confectionery products for several prominent domestic and international chocolate brands. Cannfections is a pending entrant to the Licensed Producer program for cannabis-infused products.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Tue Feb 06, 2018 5:46 pm

Cannabis Deals Cross the Billion-Dollar Mark in Canada

NetworkNewsWire Editorial Coverage: With the expected legalization of recreational cannabis use in Canada just months away, the Canadian cannabis industry is experiencing a frenzied flow of capital that is only likely to accelerate. While this capital rush won’t affect every company in the space, the overriding sentiment supports global aspirations and trickle-down opportunity for innovators like Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (LXRP Profile). This unprecedented cash flow is already fueling the construction of the largest grow facilities the world has ever seen, as well as increasingly hectic merger and acquisition strategies undertaken by companies like MedReleaf (OTC: MEDFF) (TSX: LEAF), Aurora Cannabis, Inc. (OTC: ACBFF) (TSE: ACB), Cronos Group, Inc. (OTC: PRMCF) (CVE: MJN) and Organigram Holdings, Inc. (OTC: OGRMF) (TSXV: OGI).

Reuters has reported that the value of cannabis deals this year has already reached $1.2 billion, more than double the total for 2017, which was itself a record (http://nnw.fm/14nLi). For these pioneers of pot, halcyon days lie ahead in 2018. For perspective, contrast Canada’s revenue outlook with the U.S.-based Arcview Group, which bills itself as the largest cannabis-focused investment network in the world. It has taken Arcview members several years to raise a total of US$150 million, which is no small accomplishment in a country where federal cannabis regulations can still put you in prison, but not remotely competitive against the billions being raised north of the 49th parallel.

It may be inevitable that some portion of the billions of Canadian cannabis money find their way into either developing, licensing, or buying the technology necessary to dominate the rapidly developing global legal cannabis market, and Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) has positioned itself squarely in the midst of this trend.

Lexaria’s Golden Nugget: Drug Delivery Technology

Innovators in the field of drug delivery engineer technologies to improve the targeting of therapeutic agents and their controlled release. In general, drug therapies have vastly enhanced Hippocratic practices but many come with pernicious side effects, since active agents very often cannot discriminate between healthy and unhealthy cells. Some others, although rather more benign, require large dosages or prolonged treatment since, with current delivery methods, much of the active agent is simply not absorbed by the body and goes to waste.

However, Lexaria has developed an oral digestion technology, DehydraTECH™, which improves the absorption rates of nicotine, non-steroid anti-inflammatory drugs (NSAIDs), vitamins and cannabinoids, by as much as five to 10 times. The significance of this edible technology is that this improved absorption may translate into lower dosages and shorter treatment regimens.

DehydraTECH also improves delivery times, delivering payload molecules to the bloodstream in 15-25 minutes, as opposed to 60-90 minutes for current methods. The new patented, disruptive drug delivery platform changes the way Active Pharmaceutical Ingredients (APIs) enter the body orally. The technology eliminates the need to add high concentrations of sweeteners, since it masks unwanted tastes. But, more importantly, it avoids first-pass liver metabolism, which mitigates side effects and improves the bioavailability of its client drug.

Ingestion of a medication, typically, follows a prescribed path. After the digestive system absorbs the ingredients, they are moved to the hepatic portal system en route to the liver. The liver, which among other things converts foods into the nutrients that can be used by the body, dutifully embarks on its routine of metamorphosis. Unfortunately, many therapeutic agents are neutralized in the process, which is why those that bypass the liver, using DehydraTECH for instance, tend to be more effective.

Edible Integration

DehydraTECH has already proven its mettle as Lexaria has deployed the innovative delivery platform to its product line. This consists of distinct brands: ViPova and TurboCBD. ViPova is a delicious Chinese black tea from the province of Yunnan, made from hemp oil infused within dried evaporated non-fat milk. Introduced in January 2015, the tea is available in a variety of flavors. In addition, there is Lexaria’s TurboCBD, a brand of technologically enhanced, high absorption hemp oil capsules that came to market in March 2017. TurboCBD’s cannabinoid content is fortified with high-quality American ginseng and ginkgo biloba to support enhanced focus and memory while reducing stress and fatigue.

Lexaria’s Engine of Growth is its Drug Delivery Platform

Despite the refreshing range of products, what’s under the hood matters more. Since the DehydraTECH technology can be used to improve the delivery of a wide range of substances, including ibuprofen, nicotine, fat-soluble vitamins, THC and CBD, this puts Lexaria in the enviable position of being a natural partner to cannabinoid biotech companies as their star rises, situated as an enabler rather than a competitor. Moreover, at present, Lexaria is the only company in the world that has been awarded a patent for the improved delivery (oral or ingestible, including capsules and pills) of all non-psychoactive cannabinoids.

Patents have been awarded in the United States and Australia and are pending in 40 more countries, as well as transnationally under the Patent Cooperation Treaty, as Lexaria’s patent portfolio grows. The company has filed 19 patent applications that include both method and composition of matter claims. The patents issued in the United States and Australia include “Food and Beverage Compositions infused with Lipophilic Active Agents and Methods of Use thereof.”

This puts the company in the unusually advantageous position of owning proprietary technology that can deliver a vast range of non-psychoactive cannabinoid-based drugs. Lexaria has already had discussions with major pharmaceutical and other Fortune 500 companies regarding its technology. The smallest deal with any one of these could increase revenues by over $1 million; the largest by much, much more, according to CEO Chris Bunka in a recent interview (http://nnw.fm/jY9gG). Moreover, Lexaria’s licensing model will generate revenues at very little cost, leaving 90 to 100 percent of revenues as profit.

Key Developments

On Jan. 25, 2018, Lexaria announced it had entered one such technology licensing agreement with Cannfections Group Inc., which produces cannabis-infused chocolates and candies (http://nnw.fm/qLBl3). Cannfections Group has been newly established by one of Canada’s leading chocolate companies, which has over 85 years of experience in producing high quality chocolate and confectionary products. The parent company currently manufactures chocolate retail products for several leading international and domestic chocolate brands.

“By licensing our technology to Cannfections, Lexaria can now offer its commercial clients the expertise of one of Canada’s oldest and most established chocolatiers utilizing next-generation DehydraTECHTM technology,” Bunka stated in the press release. “This is a long term strategic relationship meant to offer technology, value and expertise to Licensed Producers wanting to offer the highest quality chocolate edibles available in Canada once permitted under Health Canada regulations.”

Canadian Cannabis Wheeling & Dealing

Cannabis market leaders are providing their investors with unheralded liquidity while other leaders are hot on the investment and acquisition path. And in recent weeks and months, governments in Australia, Italy, the Netherlands, Germany and elsewhere have begun to open their markets to cannabis imports and exports for the first time in history, allowing for the beginnings of a global market in cannabis trade.

MedReleaf’s (OTC: MEDFF) (TSX: LEAF) recent Initial Public Offering (IPO) of approximately $75 million is thus far the largest marijuana company IPO in North America. MedReleaf, the first and only ISO 9001 certified cannabis producer in North America, was founded just four years ago and is one of less than four dozen licensed producers and retailers of medical cannabis products in Canada. Its focus is on the supply of dried cannabis, cannabis oils, and cannabis oil capsules to qualified medical patients in Canada but it also sells various accessories, such as vaporizers and grinders. Earlier this month, the company released details of further possible capital inflows. It announced an agreement with Canaccord Genuity Corp. and GMP Securities L.P (http://nnw.fm/g1GgG) under which the two underwriters will purchase the company’s common stock in a deal valued at C$100.7 million (US$85.8).

Some of that cannabis cash is also likely to pay for Aurora Cannabis’ (OTC: ACBFF) (TSE: ACB) 800,000-square-foot state-of-the-art Aurora Sky project and help Canada’s No. 2 marijuana producer take over smaller rival CanniMed Therapeutics Inc for C$1.1 billion (US$852 million). Aurora had originally made a hostile bid capped at C$24 (US$20.45) per share for CanniMed, but this new offer was priced at C$43 (US$36.64). The deal marked the world’s biggest marijuana M&A transaction to date.

Meanwhile, the Cronos Group, Inc. (OTC: PRMCF) (CVE: MJN) is doing deals too. In January 2018, the company announced the closing of its C$46 million bought deal public offering (http://nnw.fm/Qdc3S), the proceeds of which the company has allocated toward expanding production capacity, research and development initiatives, and for general working capital purpose. Cronos Group is a geographically diversified and vertically integrated cannabis company that operates two wholly owned licensed producers (LPs) regulated under Health Canada’s Access to Cannabis for Medical Purposes Regulations (the ACMPR) and holds a portfolio of minority investments in other licensed producers. The company’s flagship LPs, Peace Naturals Project Inc. (Ontario) and Original BC Ltd. (British Columbia), are collectively situated on over 125 acres of agricultural, licensed land. Peace Naturals Project Inc. recently obtained a Dealer’s License pursuant to the Controlled Drugs and Substances Act under Health Canada. This enables the Cronos Group, through Peace, to export medical cannabis extracts, including concentrated oil and resin products, internationally.

Organigram Holdings (OTC: OGRMF) (TSXV: OGI) is also cashing in on investor optimism. The company made public its agreement with Eight Capital under which Eight Capital and others will purchase 100,000 convertible debentures at a price of $1,000 per debenture for a total of $100 million (http://nnw.fm/39euQ). The company said it intends to use part of the net proceeds of that offering to expand its domestic and overseas market presence.

Anticipated Supply Shortfall

As legalization looms in Canada, investors are opening their checkbooks to a wide range of cannabis companies. With legalization, demand for cannabis is expected to surge. There are indications that, at present, a supply shortfall could occur. In the short term, it looks like a seller’s market and the volume of funds flowing into the industry is clear evidence of that.

For more information on Lexaria, visit Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Mon Feb 12, 2018 7:42 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expanding Best-in-Class Product Line

- Lexaria has developed an oral digestion technology that may translate into lower dosages and shorter treatment regimens
- Company is expanding its edible product offerings through a licensing agreement with a Canadian cannabis chocolate manufacturer
- Lexaria continues to develop products for demonstration, testing and sales

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed DehydraTECH™, an oral digestion technology believed to improve the absorption rates of nicotine, non-steroid anti-inflammatory drugs (NSAIDs), vitamins and cannabinoids by as much as five to ten times the normal rate. The time of onset is also reduced, and effects are felt within 15 to 20 minutes versus the normal 60 to 120 minutes. This proprietary technology also eliminates the undesired taste of cannabinoid edibles. By changing the way active pharmaceutical ingredients (APIs) enter the body, the user can benefit from lower dosages and quicker effects. The bioavailability of the APIs is improved, while side effects are tempered. As a result, this technology promotes far healthier ingestion methods than smoking or vaping.

Recently, the company announced its entry into a licensing agreement with Cannfections Group Inc. This agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles. Cannfections is an infused chocolate and gummies contract manufacturer that was recently established by one of Canada’s oldest and most recognized chocolatiers. The owners of Cannfections have 85 years of experience in the chocolate-making industry that will lend to Lexaria’s long-term strategy of partnering with the world’s best to deliver best-in-class products.

Lexaria has developed various products for demonstration, testing and sales, showing wide applicability. These non-psychoactive cannabinoid products have a high-absorption hemp oil formula, are an excellent source of omegas and essential fatty acids and are engineered for physiological performance and recovery. APIs within Lexaria’s products have been shown to reduce anxiety and stress while promoting focus, offsetting pain and inflammation and supporting circulation.

The company’s sports nutrition focus resulted in its Protein Energy Bars, which are a high source of energy, fiber and protein. ViPova™ branded premium teas deliver cannabidiol in several flavors and are high in anti-oxidants. TurboCBD™ hemp oil capsules are formulated with American ginseng and ginkgo biloba for enhanced focus and memory, and reduced stress and fatigue. Mouth-melt tablets are zero-sugar, rapidly dissolve, and combine the antioxidant properties of pterostilbene with hemp oil. Finally, Lexaria’s beverages are sparkling-clear with no hint of hemp oil flavors. With a continued focus on high quality and cutting edge technology, Lexaria is investigating and will continue to pursue additional technologies.

For more information, visit the company’s website at www.LexariaEnergy.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Feb 15, 2018 5:01 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizes Oral Digestion Technology to Expand Product Line

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently announced its entry into a licensing agreement with Cannfections Group Inc. The agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles using its proprietary DehydraTECH™ oral digestion technology. An article discussing the company reads: “Lexaria has developed various products for demonstration, testing and sales, showing wide applicability. These non-psychoactive cannabinoid products have a high-absorption hemp oil formula, are an excellent source of omegas and essential fatty acids and are engineered for physiological performance and recovery. APIs within Lexaria’s products have been shown to reduce anxiety and stress while promoting focus, offsetting pain and inflammation and supporting circulation.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP)

Postby QualityStocks » Thu Feb 15, 2018 6:29 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP): IP Portfolio, Licensing and R&D are Keys to Growth in 2018

- LXRP has global patents or patents-pending in more than 40 countries, including the U.S., Australia, China, the European Union and Canada
- Company is working through a C$250,000 budget for an 18-month collaborative research agreement with the National Research Council
- Licensing is a revenue generator, with LXRP offering to license its disruptive DehydraTECH™ technology in countries where it is patented or patent-pending

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is generating revenue and knowledge through both licensing of its IP portfolio and advancement of R&D projects. It already has patents and multiple patents-pending in more than 40 countries. It has received patent approvals in the U.S. and Australia for its DehydraTECH™ delivery technology (http://nnw.fm/Diks8). Some patent applications have already reached the active patent investigation phase in China, the European Union and Canada.

LXRP is a technology disruptor for delivery of edible forms of cannabinoids. This Kelowna, British Columbia-based food bioscience company has developed a high absorption hemp oil formula, protein energy bars, exotic teas and coffee, beer and soft drinks, and capsules and mouth-melts. All of these products share qualities of high absorption and radically improved taste, as compared to other cannabis-related food products.

The Canadian Institutes of Health Research has secured $1.4 million in funding for Canadian cannabis research projects (http://nnw.fm/Swjx2). That will fund research ranging from the potential impacts of cannabis on driving, pregnancy, childhood health, youth mental health, indigenous populations and workplace health and safety (http://nnw.fm/q84ZV).

LXRP itself has signed a C$250,000 collaborative research agreement with the National Research Council (“NRC”) for an 18-month period to investigate opportunities and determine the best methods for processing lipophilic active agents within foods.

Licensing its intellectual property portfolio is a core revenue generation strategy for LXRP (http://nnw.fm/bNK6r). For example, the company’s disruptive new DehydraTECH technology is available to be licensed in areas including processed foods, supplements, vitamins, drugs and cannabinoids. To prospective licensees, LXRP can eventually transition to a definitive fee for a structure agreement between itself and a new licensee.

The company makes its technology available on either a semi-exclusive or exclusive access basis that defines licensing by geographic region(s), for a set period of time and limited to specific product categories. LXRP has suggested that it will license DehydraTECH in any of the more than 40 countries globally where it is patented or patent-pending.

For more information, visit the company’s website at www.LexariaBioscience.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1469
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Previous

Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 2 guests

cron